Modified docetaxel, cisplatin, and 5-fluorouracil (mDCF) regimen has become a new standard for the treatment of metastatic or unresectable locally advanced recurrent squamous cell carcinoma of the anus (SCCA) after demonstrating improved efficacy (12-month PFS of 47%) in the Epitopes-HPV02 trial. | Atezolizumab plus modified docetaxelcisplatin-5-fluorouracil mDCF regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma A randomized non-comparative phase II SCARCE GERCOR trial
